CATALYST PHARMACEUTICALS INC (CPRX) Stock Price & Overview
NASDAQ:CPRX • US14888U1016
The current stock price of CPRX is 24.24 USD. Today CPRX is down by -0.33%. In the past month the price increased by 1.38%. In the past year, price increased by 10.38%.
CPRX Key Statistics
- Market Cap
- 2.96B
- P/E
- 14.34
- Fwd P/E
- 12.55
- EPS (TTM)
- 1.69
- Dividend Yield
- N/A
CPRX Stock Performance
CPRX Stock Chart
CPRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CPRX. When comparing the yearly performance of all stocks, CPRX turns out to be only a medium performer in the overall market: it outperformed 61.26% of all stocks.
CPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to CPRX. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues.
CPRX Earnings
On February 25, 2026 CPRX reported an EPS of 0.41 and a revenue of 152.61M. The company beat EPS expectations (19.63% surprise) and beat revenue expectations (5.34% surprise).
CPRX Forecast & Estimates
14 analysts have analysed CPRX and the average price target is 35.19 USD. This implies a price increase of 45.17% is expected in the next year compared to the current price of 24.24.
For the next year, analysts expect an EPS growth of 14.31% and a revenue growth 7.82% for CPRX
CPRX Groups
Sector & Classification
CPRX Financial Highlights
Over the last trailing twelve months CPRX reported a non-GAAP Earnings per Share(EPS) of 1.69. The EPS increased by 29.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 36.39% | ||
| ROA | 19.41% | ||
| ROE | 22.46% | ||
| Debt/Equity | 0 |
CPRX Ownership
CPRX Latest News, Press Relases and Analysis
CPRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.85 | 410.651B | ||
| AMGN | AMGEN INC | 16.4 | 197.945B | ||
| GILD | GILEAD SCIENCES INC | 16.14 | 180.072B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 116.919B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 80.868B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.87 | 42.343B | ||
| INSM | INSMED INC | N/A | 30.619B | ||
| NTRA | NATERA INC | N/A | 27.941B | ||
| BIIB | BIOGEN INC | 12.15 | 27.603B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 21.26B | ||
| MRNA | MODERNA INC | N/A | 21.03B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.746B | ||
| EXAS | EXACT SCIENCES CORP | 309.36 | 19.715B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CPRX
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 182 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Company Info
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134 US
CEO: Patrick J. McEnany
Employees: 182
Phone: 13055292522
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What does CATALYST PHARMACEUTICALS INC do?
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 182 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
What is the current price of CPRX stock?
The current stock price of CPRX is 24.24 USD. The price decreased by -0.33% in the last trading session.
What is the dividend status of CATALYST PHARMACEUTICALS INC?
CPRX does not pay a dividend.
How is the ChartMill rating for CATALYST PHARMACEUTICALS INC?
CPRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for CPRX stock?
14 analysts have analysed CPRX and the average price target is 35.19 USD. This implies a price increase of 45.17% is expected in the next year compared to the current price of 24.24.
What is the ex-dividend date for CPRX stock?
The next ex-dividend date for CATALYST PHARMACEUTICALS INC (CPRX) is November 7, 2022.
Would investing in CATALYST PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CPRX.